Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Purchased by Everhart Financial Group Inc.

Everhart Financial Group Inc. increased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 13.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,046 shares of the medical equipment provider’s stock after acquiring an additional 368 shares during the period. Everhart Financial Group Inc.’s holdings in Intuitive Surgical were worth $1,496,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Intuitive Surgical by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after acquiring an additional 493,126 shares during the last quarter. Capital World Investors raised its stake in Intuitive Surgical by 1.0% in the 1st quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock worth $2,907,079,000 after acquiring an additional 73,634 shares during the last quarter. American Century Companies Inc. raised its stake in shares of Intuitive Surgical by 3.0% during the 2nd quarter. American Century Companies Inc. now owns 2,398,193 shares of the medical equipment provider’s stock valued at $1,066,837,000 after buying an additional 70,556 shares during the last quarter. Clearbridge Investments LLC raised its stake in shares of Intuitive Surgical by 1.6% during the 2nd quarter. Clearbridge Investments LLC now owns 1,981,297 shares of the medical equipment provider’s stock valued at $881,380,000 after buying an additional 30,449 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in shares of Intuitive Surgical by 15.4% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,483,406 shares of the medical equipment provider’s stock valued at $659,893,000 after buying an additional 197,841 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

ISRG stock opened at $535.75 on Tuesday. The firm has a market cap of $190.82 billion, a PE ratio of 86.13, a PEG ratio of 5.27 and a beta of 1.39. The firm’s 50 day moving average price is $493.92 and its 200-day moving average price is $452.79. Intuitive Surgical, Inc. has a one year low of $281.12 and a one year high of $542.59.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating the consensus estimate of $1.24 by $0.32. The firm had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. Equities research analysts predict that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ISRG. Stifel Nicolaus raised their target price on Intuitive Surgical from $475.00 to $525.00 and gave the company a “buy” rating in a research report on Friday, October 18th. The Goldman Sachs Group set a $604.00 target price on Intuitive Surgical in a research report on Friday, October 18th. Robert W. Baird raised their target price on Intuitive Surgical from $503.00 to $565.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Citigroup raised their target price on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Finally, JPMorgan Chase & Co. raised their target price on Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. One analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus target price of $513.74.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the sale, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CEO Gary S. Guthart sold 18,151 shares of the company’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the sale, the chief executive officer now owns 24,219 shares of the company’s stock, valued at approximately $12,391,166.97. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the sale, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 68,006 shares of company stock valued at $33,727,766 over the last quarter. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.